Allied Biotech Corporation
Allied Biotech Corporation, a leading name in the biotechnology sector, is headquartered in Taiwan (TW) and operates extensively across Asia, Europe, and North America. Founded in 1995, the company has established itself as a pioneer in the development of innovative biopharmaceuticals and advanced drug delivery systems. Specialising in the production of high-quality excipients and active pharmaceutical ingredients (APIs), Allied Biotech is renowned for its commitment to quality and regulatory compliance. Their unique offerings, including proprietary formulations and customised solutions, cater to a diverse range of therapeutic areas. With a strong market position, Allied Biotech has achieved significant milestones, including numerous partnerships with global pharmaceutical companies. Their dedication to research and development continues to drive advancements in the industry, solidifying their reputation as a trusted partner in biopharmaceutical innovation.
DitchCarbon Score
How does Allied Biotech Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Allied Biotech Corporation's score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Allied Biotech Corporation's reported carbon emissions
In 2023, Allied Biotech Corporation reported total carbon emissions of approximately 5,519,770 kg CO2e. This figure represents a decrease from 2022, when emissions were about 5,718,830 kg CO2e, and from 2021, which saw emissions of around 5,545,940 kg CO2e. The company has set ambitious reduction targets, aiming for a 10% reduction in total carbon emissions across both Scope 1 and Scope 2 by the end of 2023, starting from 2021 levels. Allied Biotech's emissions data does not specify Scope 3 emissions, and there is currently no disclosed data regarding these emissions. The company has not cascaded emissions data from any parent organisation, indicating that its reported figures are independently sourced. The commitment to reducing emissions aligns with industry standards for climate action, reflecting a proactive approach to sustainability. The reduction targets are documented in their annual report, which outlines the company's strategy to mitigate its carbon footprint effectively.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Allied Biotech Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
